A study of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

Submission date	Recruitment status	Prospectively registered			
03/02/2022	No longer recruiting	☐ Protocol			
Registration date	Overall study status	Statistical analysis plan			
10/05/2022	Completed	[X] Results			
Last Edited	Condition category	[] Individual participant data			
04/10/2024	Skin and Connective Tissue Diseases				

Plain English summary of protocol

Background and study aims

Plaque psoriasis is a common, chronic, inflammatory condition, affecting about 3.5 million patients in the United States, European Union, and Japan. Despite several advanced treatment options, a large proportion of patients are not receiving these therapies and there is a need for safer options, fewer injections, and options for more effective oral medications. The investigational drug is called JNJ-77242113. It targets immune responses in the body and skin which impact diseases, such as psoriasis.

It is hoped that targeting this process may lead to less inflammation and a reduction in psoriasis disease activity. This study is designed to see if JNJ-77242113 is better than a placebo (dummy drug) in reducing psoriasis disease activity.

Who can participate?

Patients aged 18 years and over with moderate to severe plaque psoriasis.

What does the study involve?

This study will last for a maximum of 24 weeks and is divided into three parts:

- 1. Screening phase: 1 visit (up to 4 weeks)
- 2. Treatment phase: 7 visits (16 weeks)
- 3. Safety follow-up phase: 1 visit (4 weeks)

During study visits a variety of tests will be carried out including, but not limited to, blood pressure, heart activity, physical exam, questionnaires and blood samples. Patients will be randomly assigned to receive either oral JNJ-77242113 at one of five different dosing regimens or placebo twice a day during the treatment phase.

What are the possible benefits and risks of participating?

There is no established benefit to participants of this study. Based on scientific theory, taking JNJ-77242113 may improve symptoms of plaque psoriasis. These benefits are not guaranteed to happen and there may not be any benefit to participants by being in this study. In addition, if participants are put into treatment Group 6 (placebo) they will not receive JNJ-77242113 and will only receive placebo during this study.

Participants may experience some benefit from participation in the study that is not due to receiving study drug, but due to regular visits and assessments monitoring overall health.

Participation may help other people with psoriasis in the future.

Not all possible side effects and risks related to JNJ-77242113 are known and it is possible that unexpected side effects may arise or may be life-threatening. To minimise the risk associated with this, participants are frequently reviewed at every visit for side effects and adverse events. Participants are educated to report any such problems to the study staff without delay. Any serious adverse events that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team and the sponsor has implemented an Independent Data Review Committee. The participant information sheet, which will be signed by every participant agreeing to participate in the study, includes a detailed section outlining all known risks/side effects to participating in the study.

Where is the study run from?

Janssen-Cilag International NV is the sponsor for this study. The study will be run at multiple healthcare locations both within the UK and around the world.

When is the study starting and how long is it expected to run for? January 2022 to February 2023

Who is funding the study?

Janssen Research & Development, LLC (Belgium)

Who is the main contact?
Sarah Currie (JanssenUKRegistryQueries@its.jnj.com)

Contact information

Type(s)

Principal investigator

Contact name

Dr Andrew Pink

ORCID ID

https://orcid.org/0000-0001-5151-5539

Contact details

Guy's Hospital Great Maze Pond London United Kingdom SE1 9RT

Type(s)

Scientific

Contact name

Dr Medical Information and Product Information Enquiry

Contact details

50-100 Holmers Farm Way High Wycombe United Kingdom HP12 4DP +44 (0)800 731 8450 / 10494 567 444 medinfo@its.jnj.com

Additional identifiers

Clinical Trials Information System (CTIS)

2021-003700-41

Integrated Research Application System (IRAS)

1004415

ClinicalTrials.gov (NCT)

NCT05223868

Protocol serial number

77242113PSO2001, IRAS 1004415, CPMS 51021

Study information

Scientific Title

A Phase IIb multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Acronym

FRONTIER 1

Study objectives

Main objectives:

1. To evaluate the dose-response of JNJ-77242113 at Week 16 in participants with moderate-to-severe plaque psoriasis

Secondary objectives:

- 2. To characterize the additional efficacy of JNJ-77242113 versus placebo in participants with moderate-to-severe plaque psoriasis
- 3. To evaluate the effect of JNJ-77242113 treatment on patient-reported psoriasis severity versus placebo in participants with moderate-to-severe plaque psoriasis
- 4. To evaluate the effect of JNJ-77242113 treatment on dermatology-specific health-related quality of life versus placebo in participants with moderate-to-severe plaque psoriasis
- 5. To evaluate the effect of JNJ-77242113 treatment on general health-related quality of life versus placebo in participants with moderate-to-severe plaque psoriasis
- 6. To assess the safety and tolerability of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/04/2022, London-Westminster Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, UK; +44 (0)207 104 8066, +44 (0)207 1048236; westminster.rec@hra.nhs.uk), ref: 22/LO/0125

Study design

Multicentre double-blind parallel-group randomized placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Plaque psoriasis

Interventions

The total duration of this study is up to 24 weeks which includes a screening period of less than or equal to (≤) 4 weeks, a 16-week treatment period, and a 4-week safety follow-up period. Participants will be randomly assigned to one of 6 treatment arms by an online interactive web randomisation system tool. Each active cohort group will also receive a placebo to maintain blinding of dose regimens throughout the trial:

Group 1 will receive dose 1 of JNJ-77242113 once daily and placebo Group 2 will receive dose 2 of JNJ-77242113 once daily and placebo Group 3 will receive dose 3 of JNJ-77242113 once daily and placebo Group 4 will receive dose 1 of JNJ-77242113 twice daily and placebo Group 5 will receive dose 3 of JNJ-77242113 twice daily and placebo Group 6 will receive placebo twice daily

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

JNJ-77242113

Primary outcome(s)

Percentage of participants achieving Psoriasis Area Severity Index (PASI) 75 score (greater than or equal to $[\ge]$ 75 percentage [%] improvement from baseline in PASI) determined at Week 16. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

Key secondary outcome(s))

- 1. Change from baseline in PASI Total Score reported at Week 16. Change from baseline in PASI total score will be minored from baseline to week 16 and reported at Week 16
- 2. Percentage of participants achieving PASI 90 score (≥90% improvement from baseline in PASI) determined at Week 16
- 3. Percentage of participants achieving PASI 100 score (100% improvement from baseline in PASI) determined at Week 16
- 4. Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) determined at Week 16. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)
- 5. Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) determined at Week 16
- 6. Change from baseline in Body Surface Area (BSA) reported at Week 16. Body Surface Area is a commonly used measure of severity of skin disease. It is defined as the percentage of the surface area of the body involved with the condition being assessed, (that is, plaque psoriasis)
- 7. Change from baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores reported at Week 16. The PSSD includes a patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two subscores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
- 8. Change from baseline in PSSD Signs Score reported at Week 16
- 9. Percentage of participants achieving PSSD Symptoms Score = 0 determined at Week 16 in participants with a baseline Symptoms Score ≥1
- 10. Percentage of participants achieving PSSD Sign Score = 0 determined at Week 16 in participants with a baseline Sign Score ≥1
- 11. Percentage of participants achieving a Dermatology Life Quality Index (DLQI) of 0 or 1 determined at Week 16 in participants with baseline DLQI Score >1. The DLQI is a dermatology-specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past 7 days and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating a greater impact on HRQoL.
- 12. Change from baseline in Patient-reported Outcomes Measurement Information System (PROMIS-29) Domain Score reported at Week 16. The PROMIS-29 is a 29-item generic HRQoL instrument assessing 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. These questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.
- 13. Percentage of participants achieving ≥5-point improvement from baseline in PROMIS-29 Domain Score determined at Week 16
- 14. Number of participants with Adverse Events (AEs) monitored up to Week 24. An adverse event (AE) is any untoward medical event that occurs in a participant administered an

investigational product, and it does not necessarily indicate only events with a clear causal relationship with the relevant investigational product

15. Number of participants with Serious Adverse Events (SAEs) monitored up to Week 24. SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Completion date

24/02/2023

Eligibility

Key inclusion criteria

- 1. Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 6 months prior to the first administration of study intervention
- 2. Participant is a candidate for phototherapy or systemic treatment for plaque psoriasis
- 3. Participant has a total body surface area (BSA) greater than or equal to (≥) 10 percent (%) at screening and baseline
- 4. Participant has a total Psoriasis area and severity index (PASI) ≥12 at screening and baseline
- 5. Participant has a total Investigator global assessment (IGA) ≥3 at screening and baseline

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

- 1. Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
- 2. Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
- 3. Participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (IL-23R) (including but not limited to guselkumab, tildrakizumab, or risankizumab)
- 4. Participant has received any therapeutic agent directly targeted to interleukin 17 receptor (IL-17) or interleukin 12/23 receptor (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor [TNF]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention
- 5. Participant has received agents that deplete B cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention

Date of first enrolment 24/01/2022

Date of final enrolment 17/10/2022

Locations

Countries of recruitment United Kingdom

England

Canada

Czech Republic

France

Germany

Japan

Korea, South

Poland

Spain

Taiwan

United States of America

Study participating centre Castle Hill Hospital Cottingham United Kingdom HU16 5JQ

Study participating centre Pinderfields Hospital Aberford Road Wakefield United Kingdom WF1 4DG

Study participating centre Russells Hall Hospital

Pensnett Road Dudley United Kingdom DY1 2HQ

Study participating centre Guy's and St Thomas' Hospitals

Trust Offices
Guy's Hospital
Great Maze Pond
London
United Kingdom
SE1 9RT

Study participating centre Southampton General Hospital

Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre Innovaderm Research

3530 Boulevard Saint-Laurent Montreal Canada H2X 2V1

Study participating centre Skin Centre For Dermatology

775 Monaghan Road Peterborough Canada K9J 5K2

Study participating centre Dr. Chih-Ho Hong Medical 15300 105 Avenue Surrey

Canada V3R 6A7

Study participating centre Dermedge Research

333 Lakeshore Road West Mississauga Canada L4Y 4C5

Study participating centre K. Papp Clinical Research

135 Union Street East Waterloo Canada N2J 1C4

Study participating centre Dermatology Research Institute Inc.

8500 Blackfoot Trail SE Calgary Canada T2J 7E1

Study participating centre Xlr8 Medical Research

2425 Tecumseh Road East Windsor Canada N8W 1E6

Study participating centre Dermatrials Research

25 Charlton Avenue East Hamilton Canada L8N 1Y2

Fakultni Nemocnice Kralovske Vinohrady

Srobarova 50 Praha Czech Republic 775 20

Study participating centre Fn Plzen Dermatovenerologicka Klinika (Main)

Edvarda Benese 13 Plzen Czech Republic 305 99

Study participating centre Ccbr Klinicka Centra Czech, A.S.

Trida Miru 2800 Pardubice Czech Republic 53002

Study participating centre Nemocnice Ceske Budejovice, A.S.

Bozeny Nemcove 54 Ceske Budejovice Czech Republic 37087

Study participating centre Vseobecna Fakultní Nemocnice

U Nemocnice 2 Praha 2 Czech Republic 128 08

Study participating centre Dermamedica S.R.O.

Komenského 420 Nachod Czech Republic 547 01

Study participating centre Clintrial S.R.O.

Pocernicka 1427/16 Praha Czech Republic 10 100 00

Study participating centre Nemocnice Na Bulovce

Budínova 67/2 Praha 8 Czech Republic 180 81

Study participating centre Praglandia, S.R.O.

Ostrovskeho 253/3 Prague Czech Republic 15000

Study participating centre Dermatologie Prof. Hercogove

Chlumcanskeho 497/5 Prague Czech Republic 180 81

Study participating centre Ccr Prague S.R.O.

Vinohradska 1597/174 Praha Czech Republic 130 00

Study participating centre Hia Sainte Anne

2 boulevard Sainte Anne Toulon

Study participating centre Hopital Charles Nicolle

1 rue de Germont Rouen France 76031

Study participating centre Hôpital Edouard Herriot

5 Pl D Arsonval Lyon Cedex 03 France 69437

Study participating centre Centre Hospitalier Le Mans

194 Avenue Rubillard Le Mans France 72037

Study participating centre Chu Saint-Etienne

Avenue Albert Raimond St Priest En Jarez France 42270

Study participating centre Polyclinique De Courlancy

38bis Rue de Courlancy Reims France 51100

Chu De Grenoble - Hôpital Albert Michallon

Boulevard de la Chantourne La Tronche France 38700

Study participating centre Ich Hopital A. Morvan

2 Avenue Marechal Foch Brest France 29200

Study participating centre Universitatsklinikum Carl Gustav Carcus Dresden

Fetscherstr. 74 Dresden Germany 01307

Study participating centre Mensingderma Research Gmbh

Heegbarg 4 Hamburg Germany 22391

Study participating centre Universitatsklinikum Schleswig-Holstein - Kiel

Arnold-Heller-Str. 3, Haus 19 Kiel Germany 24105

Study participating centre Praxis Für Dermatologie Und Venerologie

Hauptstrasse 36a Dresden Germany 01097

Study participating centre Rothhaar Studien Gmbh

Dermatologisches Studienzentrum Berlin Germany 10783

Study participating centre Hautarztpraxis

Annenstraße 151 Witten Germany 58453

Study participating centre Charite - Universitatsmedizin Berlin (Ccm)

Charitéplatz 1 Berlin Germany 10117

Study participating centre Uniklinik Münster -Klinik U. Pol. F. Hautkrankheiten

Von-Esmarch-Straße 58 Munster Germany 48149

Study participating centre Niesmann & Othlinghaus Gbr

Alleestraße 80 Bochum Germany 44793

Study participating centre Universitatsklinikum Frankfurt

Theodor-Stern-Kai 7
Frankfurt am Main

Germany 60590

Study participating centre Universitätsklinikum Heidelberg

Im Neuenheimer Feld 440 Heidelberg Germany 69120

Study participating centre Dermatologische Gemeinschaftspraxis

Am Bahnhof 1 Mahlow Germany 15831

Study participating centre Universitätsklinikum Leipzig Aör

Klinik f. Dermatologie Leipzig Germany 04103

Study participating centre

Isa - Interdisciplinary Study Association Gmbh

Rankestrasse 34 Berlin Germany 10789

Study participating centre

Universitätsmedizin Der Johannes Gutenberg-Universität Mainz

Langenbeckstrasse 1 Mainz Germany 55131

Fachklinik Bad Bentheim

Am Bade 1 Bad Bentheim Germany 48455

Study participating centre Rosenpark Research Gmbh

Rheinstrasse 1 Darmstadt Germany 64283

Study participating centre Universitatsklinikum Bonn

Klinik und Poliklinik für Dermatologie und Allergologie Bonn Germany 53127

Study participating centre Universitaetsklinikum Koeln

Kerpener Str. 62 Koeln Germany 50937

Study participating centre Derma-Study-Center Friedrichshafen Gmbh

Charlottenstrasse 12/1 Friedrichshafen Germany 88045

Study participating centre Seibo International Catholic Hospital

2-5-1 Nakaochiai, Shinjuku-ku Tokyo Japan 161-8521

Study participating centre Kume Clinic

1-65-2, Otorihigashimachi, Nishi Ku Osaka Fu Japan 593-8324

Study participating centre Miyata Dermatology Clinic

1147 Matsudo Matsudo Japan 271-0092

Study participating centre Sapporo Skin Clinic

2-1-1 Minami-3Jo Nishi Sapporo Japan 060-0063

Study participating centre Takagi Clinic

Nishi-sanjo Minami 4-16 Obihiro-shi Japan 080-0013

Study participating centre Yamanashi Prefectural Central Hospital

1-1-1 Fujimi, Kofu-City, Yamanashi Kofu Japan 400-8506

Study participating centre Nomura Dermatology Clinic

4-27-14 tanmachi Yokohama

Study participating centre Meiwa Hospital

4-31, Agenaruo cho Nishinomiya Japan 663-8186

Study participating centre Charme Clinique

68-5, Akiyama Matsudo-shi Japan 270-2223

Study participating centre Shizuoka Prefectural General Hospital

4-27-1, Kitaando, Aoi-ku Shizuoka Japan 420-8527

Study participating centre Kumamoto Kenhoku Hospital

550, Tamana Tamana Japan 865-0005

Study participating centre Shirasaki Dermatology Clinic

3-5-33 Ekinan Takaoka Japan 933-0871

Toyama Prefectural Central Hospital

2-2-78 Nishinagae Toyama-shi Toyama Japan 930-8550

Study participating centre Mita Dermatology Clinic

4-5-8,Shiba Minato Japan 108-0014

Study participating centre Seoul National University Bundang Hospital

82, Gumi-ro,173 Beon-gil Seongnam Korea, South 463-707

Study participating centre Konkuk University Medical Center

120-1 NeunGdong-ro, Gwangjin-Gu Seoul Korea, South 05030

Study participating centre Pusan National University Hospital

179 Gudeok-Ro Busan Korea, South 49241

Study participating centre Kyunghee University Hospital

23 Kyungheedae-Ro Seoul Korea, South 102-1703

Study participating centre Asan Medical Center

88, Olympic-ro 43-gil, Songpa-gu, Seoul Korea, South 05505

Study participating centre Seoul National University Hospital

101, Daehak-ro Seoul Korea, South 03080

Study participating centre Severance Hospital, Yonsei University Health System

50-1, Yonsei-ro, Seodaemun-gu Seoul Korea, South 03722

Study participating centre Wromedica

Mickiewicza 91 Wrocław Poland 51-685

Study participating centre

Dermodent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski S.C.

Tuberozy 3 Osielsko Poland 86031

Study participating centre Nzoz Zdrowie Osteo-Medic

ul. Wiejska 81, Bialystok

Study participating centre Dermed Centrum Medyczne Sp. Z O.O

ul. Piotrkowska 48 Lodz Poland 90-265

Study participating centre Royalderm Agnieszka Nawrocka

K.Kieślowskiego 3B/3 Warszawa Poland 02962

Study participating centre Klinika Ambroziak Estederm Sp. Z O.O

Kosiarzy 9A Warsaw Poland 02-953

Study participating centre Nzoz Specderm

Kardynala Stefana Wyszynskiego 10 lokal 11 Bialystok Poland

15-888

Study participating centre Diamond Clinic Specjalistyczne Poradnie Lekarskie

Stefana Rogozinskiego 6/U3 Krakow Poland 31-559

Hosp. Univ. I Politecni La Fe

Avda. Fernando Abril Martorell 106, Torre C, Planta 7 Valencia Spain 46026

Study participating centre Hosp. Univ. 12 De Octubre

Avda. Cordoba sn Madrid Spain 28041

Study participating centre Hosp. Univ. Germans Trias I Pujol

Ctra. De Canyet s/n Barcelona Spain 08916

Study participating centre

Hosp. De Manises

Av. De la Generalitat Valenciana 50 Valencia Spain 46940

Study participating centre Hosp. Provincial De Pontevedra

C/ Simón Bolivar s/n Pontevedra Spain 36001

Study participating centre Hosp. Univ. De Cruces

Plaza de Cruces, S/N Barakaldo Spain 48902

Study participating centre Hosp. Reina Sofia

C/ Menéndez Pidal s/n Córdoba Spain 14004

Study participating centre Hosp. Univ. De Basurto Avenida de Montevideo, 18 Bilbao Spain 48013

Study participating centre National Taiwan University Hospital

Dermatology Department Taipei City Taiwan 10048

Study participating centre Chang-Gung Memorial Hospital, Linkou Branch

No.5 Fuxing street Taoyuan Taiwan 333

Study participating centre National Cheng Kung University Hospital

138 Sheng-Li Road Tainan Taiwan 70403

Study participating centre Chang Gung Memorial Hospital

Kaohsiung Branch Kaohsiung

Study participating centre Windsor Dermatology, Pc

59 One Mile Rd Ext Ste G East Windsor United States of America 08520

Study participating centre Oregon Medical Research Center

9495 SW Locust Street Portland United States of America 97223

Study participating centre Arlington Dermatology

5301 Keystone Ct. Rolling Meadows United States of America 60008

Study participating centre Modern Research Associates

9101 N. Central Expressway Dallas United States of America 75231

Study participating centre Renstar Medical Research

21 NE 1st Ave Ocala United States of America 34470

Dawes Fretzin Clinical Research Group, Llc

7910 N Shadeland Ave Indianapolis United States of America 46250

Study participating centre University Of Pittsburgh

Department Of Dermatology 3601 5th Ave Pittsburgh United States of America 15213

Study participating centre Forcare Clinical Research, Inc.

15416 North Florida Avenue Tampa United States of America 33613

Study participating centre Clinical Partners

1524 Atwood Avenue Johnston United States of America 02919

Study participating centre Indiana Clinical Trial Center

824 Edwards Drive Plainfield United States of America 46168

Study participating centre Alliance Dermatology And Mohs Center, P.C. 4045 E Bell Rd

Phoenix United States of America 85032

Study participating centre Austin Institute For Clinical Research

1601 E Pflugerville Pkwy Pflugerville United States of America 78660

Study participating centre Dermassociates, Pc

15245 Shady Grove Road Rockville United States of America 20850

Study participating centre Virginia Clinical Research

6160 Kempville Road Norfolk United States of America 23502

Study participating centre Oregon Dermatology And Research Center

2565 NW Lovejoy Portland United States of America 97210

Study participating centre Center For Clinical Studies

1401 Binz Street Houston United States of America 77004

Study participating centre University Of Utah 243 East 6100 South

Murray United States of America 84107

Study participating centre
The South Bend Clinic Center For Research
211 N Eddy St
South Bend
United States of America
46617-2808

Study participating centre Alpha Dermatology Of Pa, Llc 670 Lawn Ave Sellersville United States of America 18960

Study participating centre Ccd Research, Pllc 1 Willowbrook Road Cromwell United States of America 06416

Study participating centre Center For Clinical Studies 451 North Texas Avenue Webster United States of America 77598

Study participating centre Hamzavi Dermatology 2950 Keewahdin Road Fort Gratiot United States of America 48059

Study participating centre Vivida Dermatology

2110 East Flamingo Road, Suite 213 Las Vegas United States of America 89119

Study participating centre Pacific Skin Institute

1495 River Park Drive Sacramento United States of America 95815

Study participating centre Synergy Clinical Research

595 Buckingham Way San Francisco United States of America 94132

Study participating centre Atlanta Dermatology, Vein & Research Center

11800 Atlantis Place Alpharetta United States of America 30022

Study participating centre Dermatology Associates

1730 Minor Avenue Seattle United States of America 98101

Study participating centre Medical Dermatology Specialists

1331 N. 7th Street Phoenix United States of America 85006

Study participating centre Premier Clinical Research

324 South Sherman Spokane United States of America 99202

Study participating centre Olympian Clinical Research

1201 S Myrtle Ave Clearwater United States of America 33756

Study participating centre Oakview Dermatology

2111 East State Street Athens United States of America 45701

Sponsor information

Organisation

Janssen (Belgium)

ROR

https://ror.org/04yzcpd71

Funder(s)

Funder type

Industry

Funder Name

Janssen Research and Development

Alternative Name(s)

Janssen R&D, Janssen Research & Development, Janssen Research & Development, LLC, Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Research & Development at Janssen, JRD, J&J PRD

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-racing?	
HRA research summary			28/06/2023	No	No	
Other unpublished results			04/10/2024		No	
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes	